Morgan Stanley analyst Shinichiro Muraoka resumed coverage of Takeda (TAK) with an Overweight rating and 6,200 yen price target Market confidence in Takeda’s new drugs has been very low due to a history of frequent failures, but with the confirmation of Phase 3 success for two new drugs – oveporexton for narcolepsy and zasocitinib for psoriasis – the firm expects trust to gradually recover, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Leerink views ‘major deal’ on Entyvio as positive for Halozyme
- Halozyme announces global collaboration, license agreement with Takeda
- Alumis price target raised to $32 from $18 at Guggenheim
- Takeda, Protagonist Therapeutics submit rusfertide new drug application to FDA
- H.C. Wainwright remains bullish on Xoma following creative Takeda deal